Thyrocare to exit radiology, sell Nueclear Healthcare stake for ₹141.4 crore
Thyrocare will sell its radiology subsidiary Nueclear Healthcare to Trovera Healthcare for ₹141.4 crore, subject to approvals, sharpening its focus on pathology. The company will also acquire Nueclear’s Gurugram and Hyderabad lab premises for ₹20.59 crore.
What happened
Thyrocare Technologies · Thyrocare plans to sell its radiology subsidiary Nueclear Healthcare to Trovera for ₹141.4 crore, exiting diagnostic imaging to focus
Key facts
- ₹141.4 crore total consideration
- ₹59.5 crore in Trovera CCPS
- ₹81.9 crore cash consideration
- 1.11 crore Nueclear Healthcare equity shares
- 42,500 Trovera CCPS at ₹14,000 each
- 4.5% fully diluted Trovera share capital
- ₹20.59 crore for land and buildings
- FY26 Nueclear turnover: ₹44.62 crore
- 5.38% of Thyrocare consolidated turnover
- ₹83.55 crore Nueclear net worth
- 14.27% of Thyrocare consolidated net worth
- Thyrocare shares rose 3.22% to ₹573.70
Why this matters
The transaction creates a cleaner pathology-led portfolio for Thyrocare while giving Trovera an entry into radiology through the acquisition of Nueclear Healthcare.
What to watch
- Transaction closing timeline and any conditions imposed by regulators or counterparties.
- Management disclosure on the sale's gain/loss, tax impact and planned use of proceeds.
- Pathology revenue growth and EBITDA margin trend after the radiology exit.
- Customer/referral retention in cities where Nueclear had meaningful imaging presence.
- Any ongoing commercial partnership between Thyrocare and Trovera/Nueclear.
- New pathology lab openings, automation investments, acquisitions or capital-return announcements.
- Complete regulatory and contractual approvals for the ₹141.4 crore Nueclear stake sale.
- Acquire and integrate the Gurugram and Hyderabad laboratory premises for ₹20.59 crore.
- Redeploy sale proceeds toward pathology lab expansion, automation, logistics, technology, debt reduction or shareholder returns.
- Establish referral or service agreements with Trovera/Nueclear to retain access to imaging demand from Thyrocare's customer and physician network.
- Communicate revised segment economics, pathology growth priorities and treatment of divestment proceeds to investors.